Literature DB >> 21475230

Trastuzumab resistance: all roads lead to SRC.

Senthil K Muthuswamy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21475230     DOI： 10.1038/nm0411-416

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  14 in total

Review 1.  Trastuzumab--mechanism of action and use in clinical practice.

Authors:  Clifford A Hudis
Journal:  N Engl J Med       Date:  2007-07-05       Impact factor: 91.245

2.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

Authors:  J Baselga; D Tripathy; J Mendelsohn; S Baughman; C C Benz; L Dantis; N T Sklarin; A D Seidman; C A Hudis; J Moore; P P Rosen; T Twaddell; I C Henderson; L Norton
Journal:  J Clin Oncol       Date:  1996-03       Impact factor: 44.544

3.  Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Authors:  Harold J Burstein; Yan Sun; Luc Y Dirix; Zefei Jiang; Robert Paridaens; Antoinette R Tan; Ahmad Awada; Anantbhushan Ranade; Shunchang Jiao; Gary Schwartz; Richat Abbas; Christine Powell; Kathleen Turnbull; Jennifer Vermette; Charles Zacharchuk; Rajendra Badwe
Journal:  J Clin Oncol       Date:  2010-02-08       Impact factor: 44.544

Review 4.  Untangling the ErbB signalling network.

Authors:  Y Yarden; M X Sliwkowski
Journal:  Nat Rev Mol Cell Biol       Date:  2001-02       Impact factor: 94.444

5.  Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers.

Authors:  Ritwik Ghosh; Archana Narasanna; Shizhen Emily Wang; Shuying Liu; Anindita Chakrabarty; Justin M Balko; Ana María González-Angulo; Gordon B Mills; Elicia Penuel; John Winslow; Jeff Sperinde; Rajiv Dua; Sailaja Pidaparthi; Ali Mukherjee; Kim Leitzel; Wolfgang J Kostler; Allan Lipton; Michael Bates; Carlos L Arteaga
Journal:  Cancer Res       Date:  2011-02-15       Impact factor: 12.701

6.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.

Authors:  Siyuan Zhang; Wen-Chien Huang; Ping Li; Hua Guo; Say-Bee Poh; Samuel W Brady; Yan Xiong; Ling-Ming Tseng; Shau-Hsuan Li; Zhaoxi Ding; Aysegul A Sahin; Francisco J Esteva; Gabriel N Hortobagyi; Dihua Yu
Journal:  Nat Med       Date:  2011-03-13       Impact factor: 53.440

Review 7.  Advances in targeting SRC in the treatment of breast cancer and other solid malignancies.

Authors:  Erica L Mayer; Ian E Krop
Journal:  Clin Cancer Res       Date:  2010-07-15       Impact factor: 12.531

8.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

9.  PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Authors:  Yoichi Nagata; Keng-Hsueh Lan; Xiaoyan Zhou; Ming Tan; Francisco J Esteva; Aysegul A Sahin; Kristine S Klos; Ping Li; Brett P Monia; Nina T Nguyen; Gabriel N Hortobagyi; Mien-Chie Hung; Dihua Yu
Journal:  Cancer Cell       Date:  2004-08       Impact factor: 31.743

10.  Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.

Authors:  Yiling Lu; Qinghua Yu; Jue Hui Liu; Jinyi Zhang; Hongwei Wang; Dimpy Koul; John S McMurray; Xianjun Fang; W K Alfred Yung; Kathy A Siminovitch; Gordon B Mills
Journal:  J Biol Chem       Date:  2003-07-17       Impact factor: 5.157
View more
  16 in total

1.  Trastuzumab-Based Photoimmunotherapy Integrated with Viral HER2 Transduction Inhibits Peritoneally Disseminated HER2-Negative Cancer.

Authors:  Michihiro Ishida; Shunsuke Kagawa; Kyoko Shimoyama; Kiyoto Takehara; Kazuhiro Noma; Shunsuke Tanabe; Yasuhiro Shirakawa; Hiroshi Tazawa; Hisataka Kobayashi; Toshiyoshi Fujiwara
Journal:  Mol Cancer Ther       Date:  2016-02-01       Impact factor: 6.261

2.  Expression profiling during mammary epithelial cell three-dimensional morphogenesis identifies PTPRO as a novel regulator of morphogenesis and ErbB2-mediated transformation.

Authors:  Min Yu; Guang Lin; Niloofar Arshadi; Irina Kalatskaya; Bin Xue; Syed Haider; Francis Nguyen; Paul C Boutros; Ari Elson; Lakshmi B Muthuswamy; Nicholas K Tonks; Senthil K Muthuswamy
Journal:  Mol Cell Biol       Date:  2012-07-30       Impact factor: 4.272

Review 3.  Predictive biomarkers: a paradigm shift towards personalized cancer medicine.

Authors:  Nicholas B La Thangue; David J Kerr
Journal:  Nat Rev Clin Oncol       Date:  2011-08-23       Impact factor: 66.675

4.  Disruption of FOXO3a-miRNA feedback inhibition of IGF2/IGF-1R/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer.

Authors:  Liyun Luo; Zhijie Zhang; Ni Qiu; Li Ling; Xiaoting Jia; Ying Song; Hongsheng Li; Jiansheng Li; Hui Lyu; Hao Liu; Zhimin He; Bolin Liu; Guopei Zheng
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

5.  Drugs for solid cancer: the productivity crisis prompts a rethink.

Authors:  Daniel Rösel; Jan Brábek; Pavel Veselý; Michael Fernandes
Journal:  Onco Targets Ther       Date:  2013-06-26       Impact factor: 4.147

6.  Caveolin-1 Dependent Endocytosis Enhances the Chemosensitivity of HER-2 Positive Breast Cancer Cells to Trastuzumab Emtansine (T-DM1).

Authors:  Yuan-Chiang Chung; Jang-Fang Kuo; Wan-Chen Wei; King-Jen Chang; Wei-Ting Chao
Journal:  PLoS One       Date:  2015-07-14       Impact factor: 3.240

7.  p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy.

Authors:  Brigitte Bisaro; Marianna Sciortino; Shana Colombo; Maria Pilar Camacho Leal; Andrea Costamagna; Isabella Castellano; Filippo Montemurro; Valentina Rossi; Giorgio Valabrega; Emilia Turco; Paola Defilippi; Sara Cabodi
Journal:  Oncotarget       Date:  2016-01-26

Review 8.  Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer.

Authors:  M S N Mohd Sharial; J Crown; B T Hennessy
Journal:  Ann Oncol       Date:  2012-08-02       Impact factor: 32.976

9.  GeneSense: a new approach for human gene annotation integrated with protein-protein interaction networks.

Authors:  Zhongzhong Chen; Tianhong Zhang; Jun Lin; Zidan Yan; Yongren Wang; Weiqiang Zheng; Kevin C Weng
Journal:  Sci Rep       Date:  2014-03-26       Impact factor: 4.379

10.  PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy.

Authors:  Yi-Teng Huang; Fei-Fei Li; Chen Ke; Zhou Li; Zong-Tai Li; Xiao-Fang Zou; Xiao-Xuan Zheng; Yu-Ping Chen; Hao Zhang
Journal:  J Transl Med       Date:  2013-10-03       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.